Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021983 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021983: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00021983 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021983, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia. PURPOSE: Phase I trial to study the effectiveness of BL22 immunotoxin in treating patients who have refractory or recurrent hairy cell leukemia.
Interventions
- BIOLOGICAL BL22 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021983
The ClinicalTrials.gov registry entry for NCT00021983 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BL22 immunotoxin is the first listed.
NCT00021983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021983 about?
NCT00021983 is a clinical study titled "Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia". RATIONALE: An immunotoxin can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia. PURPOSE: Phase I trial to study the effectiveness of BL22 immunotoxin in treating patients who have refractory or recurrent hairy cell leukemia.
What is the current status of trial NCT00021983?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-12.
What interventions are being tested in trial NCT00021983?
The interventions under investigation include: BL22 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021983?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.